×
0 0 0 0 0.0418326693227091 0.0424966799468792 0.0391766268260292 0.0292164674634794
Stockreport

Cara Therapeutics launches late-stage study of CR845 in CKD-aP [Seeking Alpha]

CARA THERAPEUTICS (CARA)  More Company Research Source: Seeking Alpha
Last cara therapeutics earnings: 5/9 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.caratherapeutics.com/investor-relations
PDF Cara Therapeutics launches late-stage study of CR845 in CKD-aPCara Therapeutics (NASDAQ:CARA)initiates a Phase 3 clinical trial assessing lead candidate IV CR845, branded as KORSUVA (difelikefalin), in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKP-aP), an intractable, intense systemic itch condition. The indication has Breakthrough Therapy status.The randomized, double-blind, placebo-controlled study will have a 12-week treatment period followed by a 52-week open-label extension period. It will evaluate the safety and efficacy of 0.5 mcg/kg of KORSUVA in 350 subjects. The primary endpoint will be proportion of patients achieving at least a three-point improvement from baseline in the weekly average of daily 24-hour itching intensity numeric rating scale (NRS) scores at week 12.KORSUVA is a peripherally actingkappa opioid receptor agonist that is also being developed for the treatment of acute and chronic pain. Its value proposition is op [Read more]

IMPACT SNAPSHOT EVENT TIME: CARA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS